InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
68,057.63
(
0.38%
)
Post# of 252713
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120144
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 03/31/2008 3:34:15 AM

Monday, March 31, 2008 3:34:15 AM

Post# of 252713
AZN Ends Crestor Study Early Due to Big Benefits

[Yet another blow for MRK and SGP.]

http://www.reuters.com/article/marketsNews/idUKL3138183920080331

>>
Mon Mar 31, 2008 2:47am EDT

LONDON, March 31 (Reuters) - AstraZeneca Plc (AZN) said on Monday it had decided to stop a clinical trial of its blockbuster cholesterol-lowering Crestor early because of the clear benefits of the medicine compared to placebo.

The so-called Jupiter study was designed to see if giving Crestor to patients with no sign of pre-existing cardiovascular disease and low to normal levels of "bad" LDL cholesterol but raised C-reactive protein (CRP) would reduce heart attacks and other major cardiovascular events.

CRP, an inflammatory biomarker, is known to be associated with heart attack risk.

The Independent Data Monitoring Board, which met on March 29, decided there was unequivocal evidence of a reduction in cardiovascular morbidity and mortality among patients on Crestor in the study.

The news is a boost for the Anglo-Swedish company's drug, which sold $2.8 billion worldwide last year. Crestor is a key product for AstraZeneca as other medicines face slower growth and the threat of generic competition.

Crestor could also benefit from current controversy over another cholesterol fighter, Vytorin, from Merck & Co. Full data on a major clinical trial of Vytorin presented at a U.S. medical meeting at the weekend failed to quell concerns it might not be as good as originally thought and an expert panel recommended that patients in future stick with statins, like Crestor.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up